Rubicon Research Ltd vs Shilpa Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Rubicon Research Ltd is ₹ 961.55 as of 05 May 15:30 . The P/E Ratio of Rubicon Research Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Shilpa Medicare Ltd changed from 18.4 on March 2021 to 82.8 on March 2025 . This represents a CAGR of 35.10% over 5 years The Market Cap of Rubicon Research Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Shilpa Medicare Ltd changed from ₹ 2721 crore on March 2021 to ₹ 6483 crore on March 2025 . This represents a CAGR of 18.96% over 5 years The revenue of Rubicon Research Ltd for the Dec '25 is ₹ 479.32 crore as compare to the Sep '25 revenue of ₹ 412.72 crore. This represent the growth of 16.14% The revenue of Shilpa Medicare Ltd for the Dec '25 is ₹ 410.54 crore as compare to the Sep '25 revenue of ₹ 371.72 crore. This represent the growth of 10.44% The ebitda of Rubicon Research Ltd for the Dec '25 is ₹ 111.91 crore as compare to the Sep '25 ebitda of ₹ 94.99 crore. This represent the growth of 17.81% The ebitda of Shilpa Medicare Ltd for the Dec '25 is ₹ 101.9 crore as compare to the Sep '25 ebitda of ₹ 109.92 crore. This represent the decline of -7.3% The net profit of Rubicon Research Ltd changed from ₹ 25.57 crore to ₹ 72.8 crore over 7 quarters. This represents a CAGR of 81.83% The net profit of Shilpa Medicare Ltd changed from ₹ 14.06 crore to ₹ 44.58 crore over 7 quarters. This represents a CAGR of 93.36% The Dividend Payout of Rubicon Research Ltd changed from -1.5 % on March 2023 to 0.18 % on March 2025 . This represents a CAGR of NaN% over 3 yearsThe Dividend Payout of Shilpa Medicare Ltd changed from 4.86 % on March 2021 to 14.01 % on March 2025 . This represents a CAGR of 23.58% over 5 years .

About Rubicon Research Ltd

Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from Rubicon Consultants Private Limited' to Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002.
The Company's status got converted from a Private Company to a Public Company, the name was changed from Rubicon Research Private Limited' to Rubicon Research Limited'.
A fresh Certificate of Incorporation dated July 23, 2024 was issued by the Central Processing Centre, Manesar, Haryana. Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products.

About Shilpa Medicare Ltd

Shilpa Medicare Limited, formerly known as Shilpa Antibiotics Private Limited was incorporated as a Private Company on November 20, 1987.
The Company changed the status to Public and the name of the Company changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.
It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets.

FAQs for the comparison of Rubicon Research Ltd and Shilpa Medicare Ltd

Which company has a larger market capitalization, Rubicon Research Ltd or Shilpa Medicare Ltd?

Market cap of Rubicon Research Ltd is 15,841 Cr while Market cap of Shilpa Medicare Ltd is 8,300 Cr

What are the key factors driving the stock performance of Rubicon Research Ltd and Shilpa Medicare Ltd?

The stock performance of Rubicon Research Ltd and Shilpa Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Rubicon Research Ltd and Shilpa Medicare Ltd?

As of May 5, 2026, the Rubicon Research Ltd stock price is INR ₹961.55. On the other hand, Shilpa Medicare Ltd stock price is INR ₹424.4.

How do dividend payouts of Rubicon Research Ltd and Shilpa Medicare Ltd compare?

To compare the dividend payouts of Rubicon Research Ltd and Shilpa Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.